Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Single intravenous (iv) administration of Caplacizumab Dose 1

Single intravenous (iv) administration of Caplacizumab Dose 2

Single subcutaneous (sc) administration of Caplacizumab Dose 2

Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days

Single intravenous (iv) administration of Placebo

Single subcutaneous (sc) administration of Placebo

Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days